Antoni Ribas, MD

Dr. Antoni Ribas is a physician-scientist and leading authority on melanoma immunotherapy and targeted therapy at UCLA. His research addresses primary and acquired resistance to immunotherapy and targeted therapies for melanoma. He played instrumental roles in the clinical development of multiple FDA-approved cancer treatments including pembrolizumab, vemurafenib, cobimetinib, dabrafenib, trametinib, and axicabtagene ciloleucel. A past president of the American Association for Cancer Research (A